PF-05251749

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NamePF-05251749
Drug Alias NamePF-05251749PF5251749PF05251749BIIB-118
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCasein kinase I isoform alpha inhibitors
TargetsCasein kinase I isoform alpha
Therapy Area/IndicationsSleep Disorders, Circadian Rhythm
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen Inc
Active IndicationsN/A
Inactive IndicationsSleep Disorders, Circadian Rhythm

Other Information

ATC CodeN/A
Related LinksN/A